Irie, Y., Katakami, N., Mita, T., Takahara, M., Matsuoka, T., Gosho, M., … Atherosclerosis, C. S. of P. E. of A. on D. (2018). Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. https://doi.org/10.1007/s13300-018-0367-7 (Original work published 2018)

Masago, K., Fujita, S., Hata, A., Okuda, C., Yoshizumi, Y., Kaji, R., … Yatabe, Y. (2018). Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer. Pathology International. https://doi.org/10.1111/pin.12630 (Original work published 2018)

Ogawa, K., Ito, J., Fujimoto, D., Morita, M., Yoshizumi, Y., Ariyoshi, K., … Katakami, N. (2018). Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0561-5 (Original work published 2018)

Kiura, K., Yoh, K., Katakami, N., Nogami, N., Kasahara, K., Takahashi, T., … Uchida, H. (2018). Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples. Cancer Science. https://doi.org/10.1111/cas.13511 (Original work published 2018)

Hata, A., Katakami, N., Nanjo, S., Okuda, C., Kaji, R., Masago, K., … Hirata, Y. (2017). Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. Oncotarget, 8(69), 113807-113816. https://doi.org/10.18632/oncotarget.22837 (Original work published 2017)